Replimune Receives Second CRL for RP1 With Nivolumab for Treatment of Advanced Melanoma
This is the second complete response letter the manufacturer has received for this treatment regimen.
Published: 4/13/2026
News
Better Asthma Control Starts at the Pharmacy: Evidence, Interventions, and Outcomes
Community pharmacists boost asthma control by improving adherence, inhaler technique, and access—cutting exacerbations and emergency department visits.
Published: 3/20/2026
FDA Approves Icotrokinra as First Targeted Oral Peptide for Moderate-to-Severe Plaque Psoriasis
New once-daily oral peptide blocks IL‑23 receptor, delivering high skin clearance and strong safety for moderate-to-severe plaque psoriasis in ages 12+.
Published: 3/18/2026
FDA Clears Secukinumab for Adolescents With Severe Chronic Skin Disease
FDA approves secukinumab for adolescents 12 years and older with moderate to severe hidradenitis suppurativa, offering the first IL-17A option and new hope for earlier relief.
Published: 3/13/2026
Recapping AAAAI 2026: Updates on Remibrutinib and Innovative Treatments for Food Allergy, Atopic Disease, Asthma
New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.
Published: 3/6/2026
Dupilumab Reduces Asthma Exacerbations and Improves Control in Children Regardless of Asthma Duration
VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.
Published: 3/2/2026
![Patient with hives (chronic spontaneous urticaria [CSU]) -- Image credit: suriya | stock.adobe.com](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/f7c28cd2ba0b3498c4a0de7219e357228265f4ac-5472x3648.jpg?w=400&h=225&fit=crop&q=80&auto=format)
Remibrutinib Promotes Early Symptom Control in Patients With Chronic Spontaneous Urticaria
Remibrutinib, an oral Bruton tyrosine kinase inhibitor for chronic spontaneous urticaria (CSU), delivers itch and hive relief within 12 hours and sustains improvements through week 1.
Published: 2/27/2026
Tapinarof Cream Shows Early, Consistent Improvement in Sleep for Patients With Atopic Dermatitis
Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.
Published: 2/27/2026
Cetirizine and Levocetirizine Withdrawal Pruritus: What Pharmacists Need to Know About the FDA’s New Safety Warning
The FDA issued a drug safety communication regarding rare but severe pruritus associated with discontinuation of long-term use of cetirizine or levocetirizine.
Published: 2/19/2026
FDA Approves Difamilast as New Topical PDE4 Inhibitor for Atopic Dermatitis
FDA approves difamilast (Adquey), a topical PDE4 inhibitor, expanding nonsteroidal options for mild to moderate atopic dermatitis in dermatology patients 2 years and older.
Published: 2/18/2026
FDA Rolls Back Some Requirements for Isotretinoin-Containing Treatments for Acne
The updates allow for patients of reproductive age to complete pregnancy tests at home during or after treatment.
Published: 2/11/2026
Depressive Symptoms in Adults With Asthma Linked to Elevated BDNF Levels
Research reveals that patients with asthma who experience symptoms of depression show elevated BDNF levels, suggesting unique biological links between asthma severity and depressive symptoms.
Published: 1/30/2026
Early-Life Gut Bacteria Linked to Lower Risk of Allergies and Asthma in Children
New research reveals how specific gut bacteria in infants may reduce the risk of allergies and asthma, offering potential preventive strategies.
Published: 1/26/2026
Rocatinlimab Demonstrates Significant Efficacy and Safety in Phase 3 Trials for Moderate-to-Severe Atopic Dermatitis
Rocatinlimab shows promise in treating moderate-to-severe atopic dermatitis, offering significant symptom relief.
Published: 1/22/2026
How Eczema Timing, Duration, and Severity May Influence a Child’s Ability to Outgrow Food Allergies
Research reveals how eczema's timing and severity influence children's chances of outgrowing food allergies, highlighting the connection between skin health and allergy tolerance.
Published: 1/13/2026
Concomitant Use of Tirzepatide, Ixekizumab Improves PsA Disease Activity and Promotes Weight Reduction
The pivotal clinical trial supports the concomitant administration of tirzepatide and ixekizumab, which significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.
Published: 1/12/2026
Regimens, Adherence, and Adverse Events: The Role of the Pharmacist in Asthma Management
Collaborative health care efforts are needed to effectively manage asthma, and pharmacists play a key role in optimizing asthma treatment plans.
Published: 1/9/2026
Wildfire Smoke Exposure Associated With Decreased Asthma Control in Pediatric Patients
Research reveals that wildfire smoke exposure significantly impacts pediatric asthma control in the northeastern US, highlighting urgent climate health concerns.
Published: 12/29/2025
Showing 1 to 19 of 250 articles